Clinical trial · Observational
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
NCT03214172CI-TRIAL-00034721completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer-associated thrombosis
- description
- Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
- interventionNames
- Drug: Rivaroxaban (Xarelto, BAY59-7939)
Primary outcomes (3)
- measure
- Recurrent Venous thromboembolism
- timeFrame
- Retrospective analysis from November 2012 through September 2015
- description
- Derived using inpatient and outpatient medical claims
- measure
- Bleeding (based on the Cunningham algorithm)
- timeFrame
- Retrospective analysis from November 2012 through September 2015
- description
- Derived using inpatient and outpatient medical claims
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients (≥18 years-of-age) with active cancer * Patient with at least one index venous thromboembolism (VTE ) * ≥6-months of continuous eligibility prior to the index VTE event (baseline period). * Newly initiated on rivaroxaban Exclusion Criteria: * Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date * Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period
References
Publications (0)
Data not yet available
No reference posted for this study.